ArticleThe American journal of case reports2025
Management of Cesarean Section Uterine Scar Ectopic Pregnancy Type 2 Using Methotrexate: Insights from a Case Report.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Cesarean section uterine scar ectopic pregnancies (CSEP) are rare occurrences in which an embryo implants along uterine scar tissue from previous hysterotomies. These cases carry high morbidity and mortality, including risk of significant hemorrhage and uterine rupture. Society for Maternal-Fetal Medicine guidelines suggest either medical or surgical termination of these pregnancies; however, there are no current definitive recommendations for the management of these cases. Here, we present the case of a 36-year-old patient with a first-trimester CSEP who was managed with local intra-gestational methotrexate (MTX) and 6-month follow-up with beta-human chorionic gonadotropin (ß-hCG) monitoring. CASE REPORT We describe the case of a stable, asymptomatic 36-year-old patient with 2 previous low transverse cesarean sections, presenting in the early first trimester with a visualized CSEP on ultrasound. The patient was presented with medical and surgical options for management. After extensive counseling, she opted for a medical abortion with an intra-gestational MTX injection. She was monitored with serial quantitative ß-hCG measurements for 6 months before complete resolution of the terminated pregnancy, an interval significantly longer than typically observed in similar cases. She did not require additional medication doses or surgical intervention. CONCLUSIONS After a prolonged surveillance, this patient safely reached undetectable ß-hCG levels. There is great variability in the presentation, treatment, and long-term outcome of CSEPs, and management requires extensive provider-patient communication. Medical management with intra-gestational MTX, followed by close monitoring, is a viable option for treating stable, type 2 CSEP in patients who have access to reliable follow-up care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.